Volume | 5,063,239 |
|
|||||
News | - | ||||||
Day High | 1.63 | Low High |
|||||
Day Low | 1.40 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Aerovate Therapeutics Inc | AVTE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.61 | 1.40 | 1.63 | 1.41 | 1.65 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
21,153 | 5,063,239 | US$ 1.49 | US$ 7,535,327 | - | 1.40 - 32.415 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:59:48 | formt | 3,071 | US$ 1.41 | USD |
Aerovate Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
39.01M | 27.67M | - | 0 | -75.52M | -2.73 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aerovate Therapeutics News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVTE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.72 | 25.285 | 1.40 | 2.67 | 5,264,830 | -20.31 | -93.51% |
1 Month | 20.33 | 25.285 | 1.40 | 4.85 | 1,605,023 | -18.92 | -93.06% |
3 Months | 26.55 | 32.415 | 1.40 | 8.61 | 653,055 | -25.14 | -94.69% |
6 Months | 18.01 | 32.415 | 1.40 | 10.55 | 356,645 | -16.60 | -92.17% |
1 Year | 16.54 | 32.415 | 1.40 | 11.33 | 217,172 | -15.13 | -91.48% |
3 Years | 28.00 | 32.415 | 1.40 | 14.56 | 138,113 | -26.59 | -94.96% |
5 Years | 28.00 | 32.415 | 1.40 | 14.56 | 138,113 | -26.59 | -94.96% |
Aerovate Therapeutics Description
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe. |